NF-Kappa-B downregulation strategies in head and neck cancer treatment

Alpen Patel, Lindsay Miller, Khalil Ahmed, Frank Ondrey

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Objective Multiple biochemical and genetic strategies were used to downregulate early response gene NF-κB, whose activation controls squamous cell cancer-associated pathways. Study design NA cells, an oral cavity squamous cell cancer with high NF-κB activity, were cultured with biochemical NF-κB inhibitors TPCK and Calpain I inhibitor, as well as specific NF-κB antisense oligonucleotides. Cell proliferation was measured, as was NF-κB downregulation using functional luciferase reporter genes and electromobility shift assays. Results Significant downregulation of cell proliferation and NF-κB functional activity were demonstrated with either biochemical inhibitor, as well as the antisense oligonucleotides; however, additional nonspecific toxicities were observed with control antisense oligonucleotides. Conclusion and significance NF-κB is a potential target for squamous cancer treatment, as it is constitutively upregulated in vitro. Biochemical inhibition of NF-κB may be a viable treatment strategy for head and neck squamous cancers.

Original languageEnglish (US)
Pages (from-to)288-295
Number of pages8
JournalOtolaryngology - Head and Neck Surgery
Issue number3
StatePublished - Sep 2004

Bibliographical note

Funding Information:
This work was supported by the 5 M University of Minnesota Lions fund and the Department of Otolaryngology at the University of Minnesota. Dr Ahmed is supported by V.A.M.C. Research Funds.


Dive into the research topics of 'NF-Kappa-B downregulation strategies in head and neck cancer treatment'. Together they form a unique fingerprint.

Cite this